Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin, Cyclophosphamide, and Sequential Docetaxel in HRPC
NCT00005960Phase 2Unknown
- Sponsor
- Amgen
- Start
- Oct 1999
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of doxorubicin, cyclophosphamide, docetaxel in prostate cancer (PCa), sponsored by Amgen. Status: unknown.
02
Drugs
doxorubicincyclophosphamidedocetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00005960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005960.